AUS
NZ
UK
CA
USA
IND
Headlines
- Novartis’ Kisqali (ribociclib) demonstrated a 28.5% reduction in breast cancer recurrence risk when combined with endocrine therapy, according to the NATALEE study presented at ESMO Congress 2024.
- The positive data from a four-year post-hoc analysis highlights Kisqali’s effectiveness in preventing disease recurrence in patients with early breast cancer.
- Kisqali's success is evident in both primary and secondary endpoints, showing consistent benefits across various patient subgroups and suggesting a potential for improved overall survival.
Novartis announced encouraging results for its breast cancer medication Kisqali (ribociclib), based on the NATALEE study. This late-stage study, presented at the European Society for Medical Oncology (ESMO) Congress 2024, revealed that Kisqali, when used alongside endocrine therapy, lowered the risk of breast cancer recurrence by 28.5% in patients with early breast cancer, highlighting its potential within the healthcare stocks sector.
The NATALEE trial, a global Phase III study, assessed Kisqali's efficacy and safety as an additional treatment compared to endocrine therapy alone. The results indicate that Kisqali offers significant benefits beyond the standard three-year treatment period, demonstrating a continued reduction in recurrence risk.
The data, derived from a four-year post-hoc analysis, shows that Kisqali's benefits are consistent across all patient subgroups, including those with node-negative disease. The findings also reflect improvements in secondary endpoints, such as distant disease-free survival, with a potential positive impact on overall survival.
These results highlight Kisqali's potential in addressing the substantial risk of cancer recurrence in early breast cancer patients, with further follow-ups planned to refine the overall survival data.
